Evidence map›Paper›PMID 26370420›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2016

The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement.

M Arenas, Á Montero, M D de Las Peñas, M Algara

Registry-linked trialAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03972696 (OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03972696 naterminatednot on this mapstarted 2017, after this paper: background citation

OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment

TypeinterventionalSponsorGrupo de Investigación Clínica en Oncología RadioterapiaRan2017 to 2021Enrolled32ConditionsBreast CancerArmsIrradiation
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

M ArenasDepartment of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Institut d'Investigacions Sanitàries Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), C/Sant Joan, s.n., 43200, Reus, Tarragona, Spain. meritxell.arenas@gmail.com.
Á MonteroDepartment of Radiation Oncology, Centro Integral Oncólogico Clara Campal (CIOCC), University Hospital Madrid-Norte Sanchinarro, Madrid, Spain.
M D de Las PeñasDepartment of Radiation Oncology, Hospital Rey Juan Carlos, Móstoles, Madrid, Spain.
M AlgaraDepartment of Radiation Oncology, Pac Marc de Salut, Barcelona, Spain.
Hospital Universitario HM Sanchinarro · ESHospital Universitario Rey Juan Carlos · ESInstitut d'Investigació Sanitària Pere Virgili · ESParc de Salut · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary systemic therapy (PST) is changing the role of radiation therapy (RT) in breast cancer. Without randomized studies, the optimal indications for RT after PST and surgery are not clear. The present study provides consensus-based recommendations to clarify the role of RT.

methodsRadiation oncologists (n = 82; 77 % response rate) in Spain were surveyed to determine their recommendations for locoregional RT following PST and surgery.

resultsMost (98 %) specialists support whole breast irradiation after breast-conserving surgery (BCS), regardless of pathologic response to PST. In T1-T2 and T3-T4 tumours with sentinel node biopsy (SNB) prior to PST, 91 and 56 % of respondents, respectively, recommend irradiating the supraclavicular (level IV) and axillary level III nodes when nodal involvement is detected (9 and 44 % of respondents recommend irradiating these areas by independent of nodal status). If SNB is not available, 57 and 30 % of specialists agreed that the aforementioned nodal regions should be irradiated (33 and 65 % of respondents recommend irradiating these areas by independent of nodal status). Between 58 and 76 % of specialists agreed that nodal levels I and II should be irradiated in cases of insufficient lymphadenectomy or when >75 % of the resected nodes are involved.

conclusionAgreement is strong regarding the indications for local RT after PST and surgery, but less so for nodal irradiation. All patients who undergo BCS should receive RT, even with complete pathologic response. After mastectomy, RT is recommended in all node-positive stage III cases. Prospective studies will clarify indications for RT in this patient population.

Indexed as

Breast NeoplasmsConsensusFemaleHumansRadiation OncologyRadiotherapy, AdjuvantSpainSurveys and QuestionnairesBreast cancerPrimary systemic therapyRadiation therapy

Identifiers

PMID26370420
OpenAlexW1895253521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.